A randomized comparison of the efficacy and toxicity of epirubicin and doxorubicin in the treatment of patients with non-Hodgkin's lymphoma

Cancer

Volumn 82, Issue 11, 1998, Pages 2282-2288

  Nair, Reena ^a   Ramakrishnan, Gopal ^a   Nair, Narendran N ^a   Saikia, Tapan K ^a   Parikh, Purvish M ^a   Joshi, Sandhaya R ^a   Soman, Chitralekha S ^a   Mukhadan, Maryann ^a   Dinshaw, Ketayun T ^a   Advani, Suresh H ^a  

^a TATA MEMORIAL HOSPITAL   (India)

Author keywords

Anthracycline; Cardiotoxicity; Doxorubicin; Epirubicin; MUGA scan

Indexed keywords

BLEOMYCIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; METHOTREXATE; PREDNISOLONE; VINCRISTINE;

ARTICLE; CANCER GRADING; CANCER RECURRENCE; CARDIOTOXICITY; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HUMAN; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MUCOSA INFLAMMATION; NONHODGKIN LYMPHOMA; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REMISSION; SEPSIS; SURVIVAL RATE; TREATMENT FAILURE; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; ANTIBIOTICS, ANTINEOPLASTIC; DOXORUBICIN; EPIRUBICIN; FEMALE; HUMANS; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; RECURRENCE; SURVIVAL RATE;

EID: 0032100459     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19980601)82:11<2282::AID-CNCR26>3.0.CO;2-P     Document Type: Article

References (28)

1. Young RC, Ozols RF, Myers CE. The anthracycline antineoplastic drugs. N Engl J Med 1981;305:139-53.
2. Casazza AM. Antitumor activity of anthracyclines: experimental studies. In: Muggia FM, Young CW, editors. Anthracycline antibiotics in cancer therapy. Boston: Martinus Nijhoff, 1982:13-29.
3. Allen A. The cardiotoxicity of chemotherapeutic drugs. Semin Oncol 1992;19:529-42.
4. Minow RA, Benjamin RS, Gottlieb JA. Adriamycin (NSC-123127) cardiomyopathy: an overview with determination of risk factors. Cancer Chemother Rep 1975:6;195-201.
5. Bristow MR, Lopez MB, Mason JW. Efficacy and cost of cardiac monitoring in patients receiving doxorubicin. Cancer 1982;50:32-41.
6. Torti FM, Bristow MR, Howes AE. Reduced cardiotoxicity of doxorubicin delivered on a weekly schedule: assessment by endomyocardial biopsy. Ann Intern Med 1983;99:745-9.
7. Legha SS, Benjamin RS, Mackay B. Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion. Ann Intern Med 1982;96:133-9.
8. Speyer JL, Green MD, Ward C. A trial of ICRF-187 to selectively protect against chronic adriamycin toxicity: rationale and preliminary results of a clinical trial. In: Hacker MP, Lazo JS, Tritton TR, editors. Organ directed toxicities of anticancer drugs. Boston: Martinus Nijhoff, 1988:17-30.
9. Weiss RB, Clagett C, Russo M, et al. Anthracycline analogs: the past, present and future. Cancer Chemother Pharmacol 1985;3:818-26.
10. Jain KK, Casper ES, Geller NL. A prospective randomised comparison of epirubicin and doxorubicin in patients with advanced breast cancer. J Clin Oncol 1985;3:818-26.
11. Klimo P, Connors JM. MACOP-B chemotherapy for the treatment of advanced diffuse large cell lymphoma. Ann Intern Med 1985;102:596-602.
12. Dresdale A, Bonow RO, Wesley R, et al. Prospective evaluation of doxorubicin-induced cardiomyopathy resulting from postsurgical adjuvant treatment of patients with soft tissue sarcomas. Cancer 1983;52:51-60.
13. Casazza AM. Experimental evaluation of anthracycline analogs. Cancer Treat Rep 1979;63:835-44.
14. Bristow M. Rational system for cardiac monitoring in patients receiving anthracyclines [abstract]. Proc Am Soc Clin Oncol 1980;21:356.
15. Gottdiener JS, Mathisen DJ, Borer JS, et al. Doxorubicin cardiotoxicity: assessment of late ventricular dysfunction by radionuclide cineangiography. Ann Intern Med 1981;94: 430-5.
16. Brambilla C, Rossi A, Bonfante L, et al. Phase II study comparing doxorubicin (Dx) versus 4′-epidoxorubicin (Epi-Dx) in metastatic breast cancer. Communication to the Second European Conference on Clinical Oncology, Amsterdam, the Netherlands, November 2-5, 1983.
17. Armand JP, Hurteloup P, Hayat M, et al. Phase III chemotherapy comparing FAC versus FEC in advanced breast cancer: preliminary results [abstract]. Proc Am Soc Clin Oncol 1984;3:118.
18. Saad AD, Al-Ismail, Whittaker JA, Gough J. Combination chemotherapy including epirubicin for the management of non Hodgkin's lymphoma. Eur J Cancer Oncol 1987;1379-84.
19. Lena De M, Marzullo F, Colucci G, Lorusso V, Brandi M. Randomized trial with two CHOP-B regimens (with doxorubicin or epirubicin) in poor prognosis non-Hodgkin's lymphomas. Clin Trials J 1987;24:223-9.
20. Schneider AM, Straus DJ, Schluger AE, et al. Treatment results with an aggressive chemotherapeutic regimen (MACOP-B) for intermediate and high grade non-Hodgkin's lymphomas. J Clin Oncol 1990;8:94-102.
21. Weick JK, Dahlberg S, Fisher RI. Combination chemotherapy of intermediate and high grade non Hodgkin's lymphoma with MACOP-B: a Southwest Oncology Group study. J Clin Oncol 1991;9:748-53.
22. Vitolo U, Bertni M, Brusamolini E, et al. MACOP-B treatment in diffuse large cell lymphomas: identification of prognostic groups in an Italian multicenter study. J Clin Oncol 1992;10:219-27.
23. Gopal R, Nair R, Saikia TK, et al. Modified MACOP-B chemotherapy for intermediate and high grade non-Hodgkin's lymphomas. JAPI 1994;42:781-4.
24. Barrios CH, Weiss PD. MACOP-B for the treatment of large cell lymphoma: preliminary results at Washington University [Abstract 242a]. Blood 1987;70:824.
25. Froimmtchuck M, Olivatto LO, Gil RA. MACOP-B effective treatment for diffuse unfavourable non-Hodgkin's lymphomas (NHL) [Abstract C-936]. Proc Am Soc Clin Oncol 1988; 7:242.
26. Oster W, Hermann F, Lindemann A. Treatment of high and intermediate grade non-Hodgkin's lymphoma (NHL) with MACOP-B chemotherapy [Abstract C-937]. Proc Am Soc Clin Oncol 1988;7:242.
27. Reyroso EE, Sobrevilla PJ, Lara FU, et al. MACOP-B for advanced intermediate and high grade non-Hodgkin's lymphoma (NHL) with poor prognostic features: preliminary experience of the Institute Nacional de Cancerolgta Mexico [Abstract C-920]. Proc Am Soc Clin Oncol 1988;7:239.
28. Gianni AM, Brgni M, Siena S, Brambilla C, et al. High-dose chemotherapy and autologous bone marrow transplant compared with MACOP-B in aggressive B-cell lymphoma 1997;336:1290-7.